Harnessing oncolytic virus-mediated anti-tumor immunity.
作者信息
Schirrmacher Volker, Fournier Philippe
机构信息
DKFZ , Heidelberg , Germany ; IOZK , Cologne , Germany.
DKFZ , Heidelberg , Germany.
出版信息
Front Oncol. 2014 Nov 24;4:337. doi: 10.3389/fonc.2014.00337. eCollection 2014.
Abstract
摘要
相似文献
1
Harnessing oncolytic virus-mediated anti-tumor immunity.
Front Oncol. 2014 Nov 24;4:337. doi: 10.3389/fonc.2014.00337. eCollection 2014.
2
Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.
Eur J Immunol. 2016 Apr;46(4):919-28. doi: 10.1002/eji.201545915. Epub 2016 Feb 3.
3
Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Immunotherapy. 2018 Jul;10(9):779-786. doi: 10.2217/imt-2018-0009.
4
Poxvirus oncolytic virotherapy.
Expert Opin Biol Ther. 2019 Jun;19(6):561-573. doi: 10.1080/14712598.2019.1600669. Epub 2019 Apr 4.
5
Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Expert Opin Biol Ther. 2015;15(12):1757-71. doi: 10.1517/14712598.2015.1088000. Epub 2015 Oct 5.
6
Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV Cancers.
Mol Ther Oncolytics. 2018 Jul 5;10:1-13. doi: 10.1016/j.omto.2018.05.001. eCollection 2018 Sep 28.
7
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
Cancer Res. 2007 Mar 15;67(6):2840-8. doi: 10.1158/0008-5472.CAN-06-3974.
8
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
J Cancer. 2015 Jan 15;6(3):203-17. doi: 10.7150/jca.10640. eCollection 2015.
9
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Clin Cancer Res. 2015 Dec 15;21(24):5543-51. doi: 10.1158/1078-0432.CCR-14-2009. Epub 2015 Jul 17.
10
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.
Viruses. 2015 Dec 9;7(12):6506-25. doi: 10.3390/v7122953.
引用本文的文献
1
Direct oHSV Infection Induces DC Maturation and a Tumor Therapeutic Response.
Viruses. 2025 Aug 19;17(8):1134. doi: 10.3390/v17081134.
2
Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.
Front Immunol. 2023 Jan 10;13:950079. doi: 10.3389/fimmu.2022.950079. eCollection 2022.
3
Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis.
Biomedicines. 2020 Mar 16;8(3):61. doi: 10.3390/biomedicines8030061.
4
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.
Biomedicines. 2019 Aug 30;7(3):66. doi: 10.3390/biomedicines7030066.
5
Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.
Int J Mol Sci. 2017 May 20;18(5):1103. doi: 10.3390/ijms18051103.
6
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.
Viruses. 2015 Dec 9;7(12):6506-25. doi: 10.3390/v7122953.
本文引用的文献
1
Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies.
Front Oncol. 2014 Sep 11;4:224. doi: 10.3389/fonc.2014.00224. eCollection 2014.
2
Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines.
Front Oncol. 2014 Aug 12;4:217. doi: 10.3389/fonc.2014.00217. eCollection 2014.
3
Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.
Front Oncol. 2014 Jul 23;4:191. doi: 10.3389/fonc.2014.00191. eCollection 2014.
4
Oncolytic viruses as anticancer vaccines.
Front Oncol. 2014 Jul 21;4:188. doi: 10.3389/fonc.2014.00188. eCollection 2014.
5
Immunotherapeutic potential of oncolytic vaccinia virus.
Front Oncol. 2014 Jun 17;4:155. doi: 10.3389/fonc.2014.00155. eCollection 2014.
6
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.
Front Oncol. 2014 Jun 11;4:145. doi: 10.3389/fonc.2014.00145. eCollection 2014.
7
How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity?
Front Oncol. 2014 Jun 4;4:135. doi: 10.3389/fonc.2014.00135. eCollection 2014.
8
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.
Front Oncol. 2014 May 1;4:92. doi: 10.3389/fonc.2014.00092. eCollection 2014.
9
Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.
Front Oncol. 2014 Apr 22;4:85. doi: 10.3389/fonc.2014.00085. eCollection 2014.
10
Oncolytic virus-mediated reversal of impaired tumor antigen presentation.
Front Oncol. 2014 Apr 10;4:77. doi: 10.3389/fonc.2014.00077. eCollection 2014.
Zotero 插件